One patient with MBC was diagnosed with breast cancer gene–mutated triple-negative disease from the trial biopsy (HER2 score, 2+; ISH, negative), after which neoadjuvant treatment and the subsequent [18F]F-FDG PET/CT were aborted and surgery performed instead. This evidence concerns the gene ERBB2 and breast cancer.